에 대한 최신 뉴스 ImmuCell (NASDAQ:ICCC) 주식

ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

PriceSmart

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ICCC

KRUS

MANU

PSMT

수요일 오전(미 동부 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

수요일 주목해야 할 주식: 맨체스터 유나이티드, 프라이스스마트, 쿠라 스시 그리고 2종목

ImmuCell Corp

<h3>Gainers</h3>
<ul>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares increased by 10.2% to $1.51 during Thursday's after-market session. The company's market cap stands at $176.4 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 9.58% to $0.39. The market value of their outstanding shares is at $57.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock moved upwards by 7.95% to $2.85. The company's market cap stands at $2.1 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock moved upwards by 7.67% to $0.68. The company's market cap stands at $22.8 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock moved upwards by 7.43% to $0.45. The market value of their outstanding shares is at $6.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock rose 7.31% to $1.32. The company's market cap stands at $173.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares declined by 21.4% to $1.29 during Thursday's after-market session. The company's market cap stands at $43.3 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) shares fell 16.67% to $5.15. The company's market cap stands at $46.5 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares fell 15.35% to $9.49. The market value of their outstanding shares is at $836.0 million. </li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) shares decreased by 12.08% to $2.12. The market value of their outstanding shares is at $59.0 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 11.52% to $1.23. The company's market cap stands at $3.1 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares fell 8.84% to $2.53. The market value of their outstanding shares is at $82.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDRX

BDSX

CBUS

GYRE

IMMX

IMNN

NIVF

OTLK

PRME

RANI

TLSA

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock moved upwards by 202.1% to $0.1 during Wednesday's after-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock moved upwards by 53.33% to $2.07. The company's market cap stands at $12.7 million. As per the news, the Q3 earnings report came out today. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 30.21% to $4.87. The company's market cap stands at $13.3 million. As per the press release, Q1 earnings came out today. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock increased by 21.46% to $5.96. The company's market cap stands at $53.6 million. The company's, Q1 earnings came out today. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock moved upwards by 19.23% to $0.23. The company's market cap stands at $9.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares moved upwards by 15.69% to $0.33. The company's market cap stands at $9.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock declined by 11.3% to $0.09 during Wednesday's after-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock declined by 8.97% to $0.96. The market value of their outstanding shares is at $5.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock decreased by 7.25% to $0.87. The market value of their outstanding shares is at $8.1 million. As per the news, the Q2 earnings report came out today. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock declined by 6.99% to $0.21. The market value of their outstanding shares is at $2.0 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock decreased by 6.95% to $3.35. The company's market cap stands at $35.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares decreased by 6.48% to $2.31. The company's market cap stands at $191.3 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVTX

AXDX

AYTU

BNGO

CARM

CDXS

CHRO

CTXR

KLTO

ONCO

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

WIIM

ImmuCell shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

ImmuCell Q1 EPS $0.16 Up From $(0.06) YoY, Sales $8.07M Up From $7.26M YoY

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

BCDA

BITF

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BRTX

BZAI

CAAS

CANG

CCAP

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

CTSO

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

- ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the first quarter of 2025.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2025</td>
<td>2024</td>
<td>$ Increase</td>
<td>% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended March 31,</td>
<td>$8.1 million</td>
<td>$7.3 million</td>
<td>$0.8 million</td>
<td>11%</td>
</tr>
<tr>
<td>During the Six-Month Periods Ended March 31,</td>
<td>$15.8 million</td>
<td>$12.4 million</td>
<td>$3.5 million</td>
<td>28%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended March 31,</td>
<td>$27.3 million</td>
<td>$21.3 million</td>
<td>$6.0 million</td>
<td>28%</td>
</tr>
</tbody>
</table>
</figure>
 During the first quarter of 2025, the Company recorded its all-time quarterly sales record, exceeding the previous all-time high mark set during the fourth quarter of 2024 by 4%. The strong sales during the first quarter of 2025 helped, in part, reduce the backlog of orders to $4.0 million as of March 31, 2025, from $4.4 million as of December 31, 2024. Sales recorded during both the six-month and twelve-month periods ended March 31, 2025 also set all-time records for those periods.

Guidance

ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024

Management

ImmuCell Hires Timothy Fiori As CFO

General

ImmuCell Initiates Investigational Product Use Of Re-Tain

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly earnings of $0.06 per share. This is a 140 percent increase over losses of $(0.15) per share from the same period last year. The company reported $7.75 million in sales this quarter. This is a 52.10 percent increase over sales of $5.10 million the same period last year.

ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 116.2% to $8.8 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares moved upwards by 70.57% to $0.23. The company's market cap stands at $7.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares rose 25.0% to $3.6. The market value of their outstanding shares is at $143.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock moved upwards by 22.89% to $0.74. The market value of their outstanding shares is at $1.5 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) stock rose 17.05% to $5.56. The company's market cap stands at $309.2 million. </li>
<li>Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) shares increased by 15.83% to $122.51. The market value of their outstanding shares is at $5.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares decreased by 61.5% to $3.0 during Monday's pre-market session. The company's market cap stands at $182.5 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock fell 14.6% to $2.4. The company's market cap stands at $27.6 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock decreased by 11.94% to $4.5. The company's market cap stands at $40.1 million. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares declined by 10.99% to $2.27. The company's market cap stands at $63.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock fell 10.93% to $1.06. The market value of their outstanding shares is at $34.7 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 10.18% to $0.1. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

BACK

CYTH

12 Health Care Stocks Moving In Monday's Pre-Market Session

Comments

ImmuCell

뉴스

에 대한 최신 뉴스 ImmuCell (NASDAQ:ICCC) 주식

수요일, 7월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌